Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07023484 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

Study acronym: Preselect-1
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints revised (2)v2 Show 4 more changesShow less
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints revised (5)
    • Study description expanded, about 8 words
    • Study title shortened, about 14 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
About 70% of epithelial ovarian cancer patients are diagnosed at advanced stage. When primary optimal surgery is not possible, neoadjuvant chemotherapy will followed by interval debulking surgery is one treatment option. However, there is no consensus on the optimal timing of the surgery. CA125 is a well-known tumor marker in ovarian cancer. Its kinetic change has been proven to correlate with the patients' response to chemotherapy and chance of optimal resection. This study aims to utilize the kinetic change of CA125 to customize the timing of surgery for individual patients and compare this with the standard clinical practice.
Trial Details
NCT Number NCT07023484
Lead Sponsor The University of Hong Kong
Collaborators: Queen Mary Hospital, Hong Kong, United Christian Hospital, Pamela Youde Nethersole Eastern Hospital, The University of Hong Kong-Shenzhen Hospital, Sun Yat-Sen University Cancer Center
Conditions
(from sponsor)		 Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Related terms Fallopian Tube Neoplasms, Ovarian Neoplasms
Enrollment 126 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov